Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation

OBJECTIVE: To assess the cost-effectiveness of dabigatran etexilate, a new oral anticoagulant, versus warfarin and other alternatives for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation (AF). METHODS: A Markov model estimated the cost-effectiveness of dabigatra...

Descripción completa

Detalles Bibliográficos
Autores principales: Kansal, Anuraag R, Sorensen, Sonja V, Gani, Ray, Robinson, Paul, Pan, Feng, Plumb, Jonathan M, Cowie, Martin R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2012
Materias:
Heart Rhythm Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308473/
https://www.ncbi.nlm.nih.gov/pubmed/22422743
http://dx.doi.org/10.1136/heartjnl-2011-300646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308473/
https://www.ncbi.nlm.nih.gov/pubmed/22422743
http://dx.doi.org/10.1136/heartjnl-2011-300646

Ejemplares similares